|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
EP2251034B1
(en)
|
2005-12-02 |
2018-02-14 |
Icahn School of Medicine at Mount Sinai |
Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
|
|
MX357691B
(es)
|
2006-01-13 |
2018-07-19 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And |
Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
|
|
ES2642008T3
(es)
|
2007-05-11 |
2017-11-14 |
Altor Bioscience Corporation |
Moléculas de fusión y variantes de IL-15
|
|
AU2008269032B2
(en)
|
2007-06-27 |
2013-12-05 |
Novartis Ag |
Complexes of IL-15 and IL-15Ralpha and uses thereof
|
|
EP3851459B1
(en)
|
2010-09-21 |
2024-05-01 |
Altor BioScience, LLC |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
LT3401402T
(lt)
*
|
2012-06-08 |
2020-12-28 |
Alkermes Pharma Ireland Limited |
Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
|
|
EP2911684B1
(en)
|
2012-10-24 |
2019-06-19 |
Novartis Ag |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
JP2016500255A
(ja)
*
|
2012-12-11 |
2016-01-12 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
ハイスループットなレセプター：リガンド同定の方法
|
|
AU2014241843B2
(en)
|
2013-03-14 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
WO2014170032A1
(en)
|
2013-04-19 |
2014-10-23 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
CN105612175B
(zh)
*
|
2013-08-08 |
2023-05-09 |
赛腾制药 |
基于IL-15和IL-15Rαsushi结构域的调节因子
|
|
PT3030262T
(pt)
*
|
2013-08-08 |
2019-12-11 |
Inst Gustave Roussy Igr |
Composição farmacêutica de associação
|
|
ES2904276T3
(es)
|
2013-09-27 |
2022-04-04 |
Massachusetts Inst Technology |
Nanoestructuras de proteínas biológicamente activas sin vehículo
|
|
RU2689717C2
(ru)
*
|
2014-01-08 |
2019-05-28 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Гетеродимерный белок il-15 и его применения
|
|
EP4079321A1
(en)
*
|
2014-01-15 |
2022-10-26 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
|
CN106414748B
(zh)
|
2014-02-14 |
2021-05-28 |
得克萨斯州大学系统董事会 |
嵌合抗原受体及制备方法
|
|
CN107073099B
(zh)
|
2014-02-27 |
2022-09-27 |
默沙东公司 |
用于治疗癌症的联合方法
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
US10464982B2
(en)
|
2014-04-23 |
2019-11-05 |
Emory University |
Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
|
|
KR20210014210A
(ko)
*
|
2014-05-15 |
2021-02-08 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
KR102762243B1
(ko)
*
|
2014-06-30 |
2025-02-05 |
알토 바이오사이언스 엘엘씨 |
Il-15-베이즈드 분자 및 이의 사용 방법
|
|
WO2016018920A1
(en)
|
2014-07-29 |
2016-02-04 |
Admune Therapeutics Llc |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
SI3235830T1
(sl)
*
|
2014-12-19 |
2020-12-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
Proteinski kompleks interlevkina 15 in njegove uporabe
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
EP3307783B1
(en)
|
2015-06-10 |
2021-01-06 |
Emory University |
Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
|
|
CN106380521B
(zh)
*
|
2015-07-02 |
2020-12-29 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017027843A1
(en)
|
2015-08-12 |
2017-02-16 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
CA2999294A1
(en)
*
|
2015-09-25 |
2017-03-30 |
Altor Bioscience Corporation |
Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
|
|
BR112018006811A2
(en)
*
|
2015-10-06 |
2018-10-16 |
Regents Of The University Of Minnesota |
therapeutic compounds and methods
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
KR20180107257A
(ko)
|
2016-02-19 |
2018-10-01 |
난트 홀딩스 아이피, 엘엘씨 |
면역원 조절 방법 (methods of immunogenic modulation)
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
KR102463844B1
(ko)
*
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
|
EP3468581A1
(en)
*
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
WO2018011573A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
US12186342B2
(en)
|
2016-09-23 |
2025-01-07 |
The Regents Of The University Of California |
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha
|
|
PE20240950A1
(es)
*
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
JP7213180B2
(ja)
*
|
2016-10-19 |
2023-01-26 |
エフ．ホフマン－ラ ロシュ アーゲー |
免疫コンジュゲートを製造するための方法
|
|
EP3529263B1
(en)
*
|
2016-10-21 |
2025-08-06 |
Altor BioScience Corporation |
Multimeric il-15-based molecules
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
CN108250302A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
JP2020505350A
(ja)
|
2017-01-20 |
2020-02-20 |
ノバルティス アーゲー |
癌の治療のための組合せ療法
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
JP7341900B2
(ja)
|
2017-03-03 |
2023-09-11 |
オブシディアン セラピューティクス， インコーポレイテッド |
免疫療法のためのｃｄ１９組成物及び方法
|
|
KR20250150164A
(ko)
*
|
2017-03-06 |
2025-10-17 |
알토 바이오사이언스 엘엘씨 |
Il-12 및 il-18로의 il-15-기반 융합
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
AU2018245749A1
(en)
|
2017-03-27 |
2019-10-03 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
US20190048055A1
(en)
*
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
AU2018288715A1
(en)
|
2017-06-20 |
2019-12-12 |
Immunitybio, Inc. |
NK-92 cells and IL-15 agonist combination therapy
|
|
EP3641768B1
(en)
|
2017-06-21 |
2025-12-31 |
iCell Gene Therapeutics LLC |
Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
|
|
AU2018291497A1
(en)
*
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
EP3648786A4
(en)
*
|
2017-07-03 |
2021-12-15 |
Torque Therapeutics, Inc. |
FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES
|
|
PL3639845T3
(pl)
|
2017-07-25 |
2023-10-23 |
Jiangsu Hengrui Medicine Co., Ltd. |
Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
|
|
EP3676289B1
(en)
|
2017-08-28 |
2026-03-04 |
Altor BioScience, LLC |
Il-15-based fusions to il-7 and il-21
|
|
EP3678701A4
(en)
|
2017-09-05 |
2021-12-01 |
Torque Therapeutics, Inc. |
THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
|
|
JP7710644B2
(ja)
|
2017-10-12 |
2025-07-22 |
アイセル・ジーン・セラピューティクス・インコーポレイテッド |
複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
US20200384084A1
(en)
|
2017-12-01 |
2020-12-10 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
CA3086040A1
(en)
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
WO2019135958A2
(en)
|
2018-01-05 |
2019-07-11 |
Oleg Shikhman |
Surgical clip and deployment system
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP2021512104A
(ja)
|
2018-02-02 |
2021-05-13 |
ノバルティス アーゲー |
癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
|
|
SG11202007156QA
(en)
|
2018-02-09 |
2020-08-28 |
Nat Univ Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
CN112004547A
(zh)
*
|
2018-02-26 |
2020-11-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
WO2019195420A1
(en)
*
|
2018-04-04 |
2019-10-10 |
Nant Holding IP, LLC |
Advanced avartar dendritic cells
|
|
EP3781596A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
EP3781597A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
WO2019207041A1
(en)
*
|
2018-04-26 |
2019-10-31 |
F. Hoffmann-La Roche Ag |
Method of and system for tracking an animal in a population of animals
|
|
CN110437339B
(zh)
*
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US11634467B2
(en)
|
2018-06-22 |
2023-04-25 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
KR102848197B1
(ko)
*
|
2018-06-22 |
2025-08-21 |
큐진 인크. |
신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도
|
|
CA3102641A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
CN112513276B
(zh)
|
2018-07-30 |
2024-03-15 |
张晋宇 |
蛋白质异二聚体及其用途
|
|
WO2020037120A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Nantbio, Inc. |
Il7-il15 txm compositions and methods
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
US12486514B2
(en)
|
2018-08-29 |
2025-12-02 |
National University Of Singapore |
Method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
CN113365663B
(zh)
|
2018-08-30 |
2025-11-21 |
免疫生物公司 |
单链嵌合多肽和其用途
|
|
WO2020047473A1
(en)
*
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Single-chain and multi-chain chimeric polypeptides and uses thereof
|
|
KR20250160211A
(ko)
*
|
2018-08-30 |
2025-11-11 |
이뮤니티바이오, 인크. |
다중-사슬 키메라 폴리펩타이드 및 이의 용도
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
US11701408B2
(en)
*
|
2018-10-11 |
2023-07-18 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
BR112021006783A2
(pt)
|
2018-10-12 |
2021-07-13 |
Xencor, Inc. |
proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer.
|
|
CN120535653A
(zh)
|
2018-10-19 |
2025-08-26 |
明尼苏达大学董事会 |
Nk接合子分子及其使用方法
|
|
EP3876956A4
(en)
|
2018-11-08 |
2022-12-28 |
The Regents of The University of California |
SYSTEMS AND METHODS FOR TARGETING CANCER CELLS
|
|
TW202028226A
(zh)
|
2018-12-13 |
2020-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
WO2020130829A1
(en)
|
2018-12-20 |
2020-06-25 |
Merus N.V. |
Clec12axcd3 bispecific antibodies and methods for the treatment of disease
|
|
EP3908314A4
(en)
*
|
2019-01-11 |
2023-05-10 |
Memorial Sloan Kettering Cancer Center |
MULTIMERIZATION OF IL-15/IL-15R ALPHA-FC COMPLEXES TO IMPROVE IMMUNOTHERAPY
|
|
WO2020150364A1
(en)
*
|
2019-01-15 |
2020-07-23 |
Altor Bioscience, Llc |
Human immunodeficiency virus-specific t cell receptors
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
US20220218789A1
(en)
|
2019-05-10 |
2022-07-14 |
Nant Holdings Ip, Llc |
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
AU2020294797B2
(en)
|
2019-06-21 |
2025-12-18 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
JP7213976B2
(ja)
|
2019-07-08 |
2023-01-27 |
イミュニティーバイオ、インコーポレイテッド |
単核細胞由来のｎｋ細胞
|
|
US11364291B1
(en)
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
WO2021041886A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified n-810 and methods therefor
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220402988A1
(en)
*
|
2019-12-05 |
2022-12-22 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
IL294257A
(en)
*
|
2019-12-31 |
2022-08-01 |
Navrogen Inc |
The composition of engineered monoclonal antibodies that are resistant to immunosuppressive cancer factors and their use
|
|
US20230056856A1
(en)
|
2020-01-08 |
2023-02-23 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
WO2021142476A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
EP4097043A4
(en)
*
|
2020-01-31 |
2024-05-22 |
Auragent Bioscience, LLC |
ULTRABRIGHT FLUORESCENT NANOCOMPOSITE STRUCTURES FOR IMPROVED FLUORESCENT BIOASSAYS
|
|
CR20220367A
(es)
|
2020-02-05 |
2022-08-30 |
Novartis Ag |
Célula cho que expresa heterodímeros il-15
|
|
CA3169243A1
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
JP2023513573A
(ja)
|
2020-02-11 |
2023-03-31 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
加齢性および炎症性疾患を治療する方法
|
|
AU2021219720B2
(en)
|
2020-02-11 |
2025-10-02 |
Immunitybio, Inc. |
Chromatography resin and uses thereof
|
|
WO2021183717A1
(en)
|
2020-03-11 |
2021-09-16 |
Nantcell, Inc. |
Proteinaceous therapeutics
|
|
WO2021202354A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
JP2023523218A
(ja)
|
2020-04-22 |
2023-06-02 |
ノバルティス アーゲー |
ヘテロ二量体ヒトインターロイキン－１５（ｈｅｔＩＬ－１５）の医薬組成物及び医薬製品
|
|
US12497462B2
(en)
|
2020-04-29 |
2025-12-16 |
Immunitybio, Inc. |
Anti-CD26 proteins and uses thereof
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021253360A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
WO2022026577A1
(en)
|
2020-07-31 |
2022-02-03 |
Nantbio, Inc. |
Chimeric t cell receptors, nucleic acids, and methods of making and using the same
|
|
CN116437944A
(zh)
*
|
2020-08-03 |
2023-07-14 |
南特细胞公司 |
Il-15超级激动剂的药物特异性药代动力学测定
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
MX2023003112A
(es)
*
|
2020-09-16 |
2023-03-22 |
Beigene Ltd |
Constructos de interleucina 15 y metodos de uso.
|
|
TW202235431A
(zh)
|
2020-11-25 |
2022-09-16 |
美商艾希利歐發展股份有限公司 |
腫瘤特異性可裂解連接子
|
|
WO2022113056A1
(en)
|
2020-11-30 |
2022-06-02 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
JP2024501831A
(ja)
*
|
2020-12-23 |
2024-01-16 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
CN117440972A
(zh)
|
2021-03-24 |
2024-01-23 |
奥克梅斯公司 |
Upar抗体和具有所述抗体的融合蛋白
|
|
JP2024512714A
(ja)
*
|
2021-03-31 |
2024-03-19 |
アンウィタ バイオサイエンシス， インク． |
融合タンパク質、医薬組成物、及び治療適用
|
|
CN118251420A
(zh)
|
2021-04-28 |
2024-06-25 |
米诺陶治疗公司 |
人源化嵌合牛抗体和使用方法
|
|
CN116375888A
(zh)
*
|
2021-05-08 |
2023-07-04 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
EP4346875A4
(en)
*
|
2021-05-28 |
2025-04-16 |
Akso Biopharmaceutical, Inc. |
BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
|
|
CN117479831A
(zh)
|
2021-06-09 |
2024-01-30 |
南特知识产权控股有限责任公司 |
用于在植物中生产感兴趣的蛋白质的方法和系统
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
WO2023141505A1
(en)
|
2022-01-22 |
2023-07-27 |
Nantcell, Inc. |
Fusion molecules of ctla4 and il-15
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120916753A
(zh)
*
|
2023-03-29 |
2025-11-07 |
星锐医药(苏州)有限公司 |
编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
|
|
WO2024253944A2
(en)
*
|
2023-06-06 |
2024-12-12 |
Jecho Laboratories, Inc. |
Interleukin-15 fusion protein and methods of use
|
|
AU2024289944A1
(en)
*
|
2023-07-05 |
2026-01-29 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
WO2025015318A2
(en)
|
2023-07-13 |
2025-01-16 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
WO2025019077A1
(en)
|
2023-07-18 |
2025-01-23 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
US20250108112A1
(en)
*
|
2023-10-02 |
2025-04-03 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
US20250243279A1
(en)
|
2023-10-17 |
2025-07-31 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
US20250134974A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|
|
US20260001951A1
(en)
|
2024-06-28 |
2026-01-01 |
Immunitybio, Inc. |
Anti-SLAMF7 Antibodies And Therapeutics
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
WO2026024752A1
(en)
|
2024-07-23 |
2026-01-29 |
Immunitybio, Inc. |
Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
|